PE20211455A1 - Moduladores del receptor nmda espiro-lactama y usos de los mismos - Google Patents
Moduladores del receptor nmda espiro-lactama y usos de los mismosInfo
- Publication number
- PE20211455A1 PE20211455A1 PE2020001149A PE2020001149A PE20211455A1 PE 20211455 A1 PE20211455 A1 PE 20211455A1 PE 2020001149 A PE2020001149 A PE 2020001149A PE 2020001149 A PE2020001149 A PE 2020001149A PE 20211455 A1 PE20211455 A1 PE 20211455A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- group
- spiro
- independently selected
- lactama
- Prior art date
Links
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624218P | 2018-01-31 | 2018-01-31 | |
| US201862718107P | 2018-08-13 | 2018-08-13 | |
| PCT/US2019/016098 WO2019152678A1 (en) | 2018-01-31 | 2019-01-31 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211455A1 true PE20211455A1 (es) | 2021-08-05 |
Family
ID=65494516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001149A PE20211455A1 (es) | 2018-01-31 | 2019-01-31 | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210047324A1 (https=) |
| EP (1) | EP3746442A1 (https=) |
| JP (2) | JP2021512109A (https=) |
| KR (1) | KR20200115610A (https=) |
| CN (1) | CN112218866A (https=) |
| AU (1) | AU2019215049A1 (https=) |
| BR (1) | BR112020015666A2 (https=) |
| CA (1) | CA3089559A1 (https=) |
| CL (1) | CL2020001990A1 (https=) |
| IL (1) | IL276330A (https=) |
| MX (1) | MX2020008106A (https=) |
| PE (1) | PE20211455A1 (https=) |
| PH (1) | PH12020551140A1 (https=) |
| SG (1) | SG11202007251XA (https=) |
| WO (1) | WO2019152678A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151416A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| KR102465758B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| IL286107B2 (en) | 2016-08-01 | 2024-09-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
| JP7036792B2 (ja) | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
| PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| WO2024054919A1 (en) * | 2022-09-08 | 2024-03-14 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2024354932A1 (en) * | 2023-10-03 | 2026-04-09 | Revolution Medicines, Inc. | Synthesis of ras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918868B8 (pt) * | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| WO2011100585A1 (en) * | 2010-02-11 | 2011-08-18 | Joseph Moskal | Secondary structure stabilized nmda receptor modulators and uses thereof |
| CN102267995A (zh) * | 2010-06-04 | 2011-12-07 | 艾琪康医药科技（上海）有限公司 | 一种制备二氮杂螺环化合物的方法 |
| EP2951186B1 (en) * | 2013-01-29 | 2018-07-25 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9758525B2 (en) * | 2013-01-29 | 2017-09-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| JP2016506962A (ja) * | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| KR102410989B1 (ko) * | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| PE20151416A1 (es) * | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| MX379622B (es) * | 2015-04-03 | 2025-03-11 | Recurium Ip Holdings Llc | Compuestos espirociclicos |
| WO2017201285A1 (en) * | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20190174A1 (es) * | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| KR102465758B1 (ko) * | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| AR110988A1 (es) * | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| JP2022092387A (ja) * | 2020-12-10 | 2022-06-22 | キヤノン株式会社 | 画像形成装置 |
-
2019
- 2019-01-31 PE PE2020001149A patent/PE20211455A1/es unknown
- 2019-01-31 AU AU2019215049A patent/AU2019215049A1/en not_active Abandoned
- 2019-01-31 KR KR1020207024903A patent/KR20200115610A/ko not_active Withdrawn
- 2019-01-31 US US16/966,176 patent/US20210047324A1/en not_active Abandoned
- 2019-01-31 BR BR112020015666-3A patent/BR112020015666A2/pt not_active Application Discontinuation
- 2019-01-31 MX MX2020008106A patent/MX2020008106A/es unknown
- 2019-01-31 CA CA3089559A patent/CA3089559A1/en active Pending
- 2019-01-31 CN CN201980018351.6A patent/CN112218866A/zh active Pending
- 2019-01-31 EP EP19706076.7A patent/EP3746442A1/en not_active Withdrawn
- 2019-01-31 WO PCT/US2019/016098 patent/WO2019152678A1/en not_active Ceased
- 2019-01-31 JP JP2020541807A patent/JP2021512109A/ja active Pending
- 2019-01-31 SG SG11202007251XA patent/SG11202007251XA/en unknown
-
2020
- 2020-07-27 IL IL276330A patent/IL276330A/en unknown
- 2020-07-28 PH PH12020551140A patent/PH12020551140A1/en unknown
- 2020-07-30 CL CL2020001990A patent/CL2020001990A1/es unknown
-
2023
- 2023-11-10 JP JP2023192455A patent/JP2024019396A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019215049A1 (en) | 2020-09-17 |
| WO2019152678A1 (en) | 2019-08-08 |
| IL276330A (en) | 2020-09-30 |
| MX2020008106A (es) | 2020-09-25 |
| JP2021512109A (ja) | 2021-05-13 |
| CA3089559A1 (en) | 2019-08-08 |
| BR112020015666A2 (pt) | 2021-02-23 |
| KR20200115610A (ko) | 2020-10-07 |
| US20210047324A1 (en) | 2021-02-18 |
| JP2024019396A (ja) | 2024-02-09 |
| CL2020001990A1 (es) | 2021-03-26 |
| SG11202007251XA (en) | 2020-08-28 |
| CN112218866A (zh) | 2021-01-12 |
| PH12020551140A1 (en) | 2021-05-31 |
| EP3746442A1 (en) | 2020-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211455A1 (es) | Moduladores del receptor nmda espiro-lactama y usos de los mismos | |
| PE20241068A1 (es) | Moduladores de profarmacos de la via de estres integrada | |
| PE20212302A1 (es) | Inhibidores de apol1 y sus metodos de uso | |
| PE20190503A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| UY39723A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| CL2020001546A1 (es) | Compuestos de 4-azaindol. | |
| MX2023010043A (es) | Moduladores del receptor de androgenos y metodos para su uso. | |
| MX2020006460A (es) | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. | |
| CR20200403A (es) | Macrociclos como moduladores del regular de conductancia transmenbrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosisquística y procesos para elaborarlos | |
| CO2017004481A2 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
| PE20190501A1 (es) | Moduladores nmda espiro-lactam y metodos de uso de los mismos | |
| UY37310A (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
| PE20180462A1 (es) | Moduladores cot y metodos de uso de los mismos | |
| AR114803A1 (es) | Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos | |
| AR109561A1 (es) | Compuestos modulares de receptores tipo toll | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| CR20200553A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| CO2022002781A2 (es) | Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos | |
| PE20191495A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| PE20190504A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| PE20170324A1 (es) | Anticuerpos dirigidos contra cd127 | |
| AR054320A1 (es) | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas | |
| MX2020003666A (es) | Compuestos y composiciones para el tratamiento de trastornos hematologicos. | |
| CO2021000041A2 (es) | Degradadores selectivos del receptor de estrógeno |